Related Experiment Video
Updated: May 31, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Protective effect of pneumococcal vaccination on pneumococcal pneumonia outcomes: analysis adjusted for severity and
M Perea Gainza1, M A Arce Marañón1, N Miota Hernández1
1Servicio de Medicina Interna, Hospital de la Axarquía, Málaga, Spain.
Background And Objective:
Pneumococcal vaccination may attenuate the severity of pneumococcal pneumonia even in breakthrough infections. However, evidence on this effect stratified by clinical severity is scarce. The objective was to evaluate whether vaccination reduces poor outcomes in patients hospitalized for pneumococcal pneumonia, specifically according to CURB-65 severity.
Methods:
Retrospective observational study of 90 adults with microbiologically confirmed pneumococcal pneumonia (January 2020-December 2024). Poor outcome was defined as death or ICU admission. Propensity score matching (PSM) 1:1 was performed to control for indication bias, adjusting for age, sex, comorbidity, CURB-65, and dependency. In the matched sample (43 pairs), the effect of vaccination on poor outcome was analysed with logistic regression further adjusted for comorbidity and CURB-65. Sensitivity analysis was conducted with inverse probability of treatment weighting (IPTW).
Results:
Vaccinated patients had higher age, comorbidity, and CURB-65 at admission. PSM achieved adequate balance between groups. In the matched sample, poor outcome occurred in 34.9% of vaccinated and 51.2% of unvaccinated (absolute reduction 16.3%). Adjusted OR for vaccination was 0.42 (95% CI: 0.16-1.07; p = 0.070), suggesting a possible protective effect, although statistical significance was not reached. CURB-65 was an independent predictor of poor outcome (OR per point: 1.93; p = 0.006). IPTW yielded an OR of 1.28 (95% CI: 0.67-2.47; p = 0.46).
Conclusions:
Pneumococcal vaccination shows a possible protective effect, with a trend toward clinically relevant benefit, especially in patients with more severe disease (CURB-65 ≥ 3), reducing poor outcomes by 16.3%. This finding supports vaccination in adults with risk factors.
More Related Videos
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
09:12Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae
Published on: January 17, 2014
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology